BiomEdit: a new animal health company is born
Elanco and Ginkgo Bioworks are behind a project focused in the fast-growing microbiome science applied to pets.
The company aims at developing animal health products and introducing to the market novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.
Elanco will contribute intellectual property and a pipeline of ongoing programs to BiomEdit, which will be staffed with members of the former Elanco microbiome R&D team.
The company will also take advantage of the expertise of Ginkgo in the discovery, design and monitoring of microbes at scale for a wide array of functions.
Both companies are expected to retain around 40% combined proportional ownership of BiomEdit. In addition, BiomEdit launched a targeted Series A funding raise of $40 million (€37M).
Microbiome science creates breakthroughs in animal health based on the microbial communities in animals and the surrounding environment.